EPO VERSION EXHIBITING INCREASED RECEPTOR BINDING AFFINITY AND LOWER ANTIGEN POTENTIAL, DNA CODING SUCH EPO VERSION, RECOMBINANT EXPRESSION VECTOR CONTAINING SUCH DNA, HOST CELL TRANSFORMED OR TRANSFECTED BY SUCH VECTOR, METHOD FOR PRODUCING SUCH EPO VERSION AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH EPO VERSION

摘要

FIELD: medicine.;SUBSTANCE: what is offered is an erythropoietin (EPO) version which differs from an original hormone form by a replacement of an amino-acid residue in phenylalanine in the position 142 or in position 148 of a wild-type proteins for a residue in valine. New EPO muteins are characterised by higher receptor affinity as compared to a non-modified protein, and also lower antigen potential. The invention discloses a DNA sequence coding the new EPO versions, and a method for producing related recombinant products by its expression in a heterological system. It is offered to include the EPO versions under the invention in the pharmaceutical compositions intended for treating the diseases which require the use of erythropoietin.;EFFECT: higher efficacy of the composition.;6 cl, 29 dwg, 11 tbl, 11 ex